FDA Approves PYRIDOSTIGMINE BROMIDE — Amneal Pharmaceuticals LLC

# FDA Approves Amneal Pharmaceuticals' Pyridostigmine Bromide Oral Formulation Amneal Pharmaceuticals LLC received FDA approval for its oral pyridostigmine bromide formulation (NDA217604), expanding the company's presence in the neuromuscular disorder treatment market. The approval enables Amneal to compete in the established myasthenia gravis therapeutic segment, potentially capturing market share from existing branded and generic competitors.